In the multicenter phase 2 FAKTION study, treatment with capivasertib–fulvestrant significantly improved PFS and overall survival, compared with placebo–fulvestrant, among postmenopausal patients with HR-positive/HER2-negative advanced breast cancer who had previously received endocrine therapy30,31. Here, ERBB2 is linked to breast carcinoma.